Key result
Treatment with a KCa1.1 channel blocker stopped disease progression, reduced joint and bone damage, and inhibited FLS invasiveness and proliferation in rat models of rheumatoid arthritis.
Why the study?
Does KCa1.1 inhibition reduce disease progression and FLS invasiveness in rat models of rheumatoid arthritis?
Does KCa1.1 inhibition reduce disease progression and FLS invasiveness in rat models of rheumatoid arthritis?
KCa1.1 channel inhibition reduces fibroblast-like synoviocyte invasiveness and halts disease progression in rat models of rheumatoid arthritis, suggesting a potential therapeutic target.
KCa1.1 blockade should not yet change RA practice; leaves open translation from rat models to human trials.
OBJECTIVE: Fibroblast-like synoviocytes (FLS) participate in joint inflammation and damage in rheumatoid arthritis (RA) and its animal models. The purpose of this study was to define the importance of KCa1.1 (BK, Maxi-K, Slo1, KCNMA1) channel expression and function in FLS and to establish these channels as potential new targets for RA therapy. METHODS: We compared KCa1.1 expression levels in FLS from rats with pristane-induced arthritis (PIA) and in FLS from healthy rats. We then used ex vivo functional assays combined with small interfering RNA-induced knockdown, overexpression, and functional modulation of KCa1.1 in PIA FLS. Finally, we determined the effectiveness of modulating KCa1.1 in 2 rat models of RA, moderate PIA and severe collagen-induced arthritis (CIA). RESULTS: We found that PIA FLS expressed the KCa1.1 channel as their major potassium channel, as has been found in FLS from patients with RA. In contrast, FLS from healthy rats expressed fewer of these channels. Inhibiting the function or expression of KCa1.1 ex vivo reduced proliferation and invasive properties of, as well as protease production by, PIA FLS, whereas opening native KCa1.1 or overexpressing the channel enhanced the invasiveness of both FLS from rats with PIA and FLS from healthy rats. Treatment with a KCa1.1 channel blocker at the onset of clinical signs stopped disease progression in the PIA and CIA models, reduced joint and bone damage, and inhibited FLS invasiveness and proliferation. CONCLUSION: Our results demonstrate a critical role of KCa1.1 channels in the regulation of FLS invasiveness and suggest that KCa1.1 channels represent potential therapeutic targets in RA.
No takes yet. Share an insight, caveat, or question.
Tanner et al. (2014) studied Rheumatoid arthritis. KCa1.1 channel blocker was evaluated on Disease progression, joint and bone damage, and FLS invasiveness. Treatment with a KCa1.1 channel blocker stopped disease progression, reduced joint and bone damage, and inhibited FLS invasiveness and proliferation in rat models of rheumatoid arthritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: